Shares of AnaptysBio (ANAB) plunged in late morning trading after the company disclosed that its Phase 2b trial for etokimab in atopic dermatitis failed to meet its primary endpoint. Shares of rival… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id2991229/-Eczema-drug-trial-failure-sinks-AnaptysBio-boosts-rival-Dermira)